Literature DB >> 32726539

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.

Inhye E Ahn1, Xin Tian1, Adrian Wiestner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32726539      PMCID： PMC7456330          DOI： 10.1056/NEJMc2005943

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

Authors:  Susan O'Brien; Jeffrey A Jones; Steven E Coutre; Anthony R Mato; Peter Hillmen; Constantine Tam; Anders Österborg; Tanya Siddiqi; Michael J Thirman; Richard R Furman; Osman Ilhan; Michael J Keating; Timothy G Call; Jennifer R Brown; Michelle Stevens-Brogan; Yunfeng Li; Fong Clow; Danelle F James; Alvina D Chu; Michael Hallek; Stephan Stilgenbauer
Journal:  Lancet Oncol       Date:  2016-09-13       Impact factor: 41.316

3.  Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Authors:  Tait D Shanafelt; Xin V Wang; Neil E Kay; Curtis A Hanson; Susan O'Brien; Jacqueline Barrientos; Diane F Jelinek; Esteban Braggio; Jose F Leis; Cong C Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Richard F Little; Harry Erba; Richard M Stone; Mark Litzow; Martin Tallman
Journal:  N Engl J Med       Date:  2019-08-01       Impact factor: 91.245

4.  Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Jasmin Bahlo; Anna-Maria Fink; Maneesh Tandon; Mark Dixon; Sandra Robrecht; Simon Warburton; Kathryn Humphrey; Olga Samoylova; Anna M Liberati; Javier Pinilla-Ibarz; Stephen Opat; Liliya Sivcheva; Katell Le Dû; Laura M Fogliatto; Carsten U Niemann; Robert Weinkove; Sue Robinson; Thomas J Kipps; Sebastian Boettcher; Eugen Tausch; Rod Humerickhouse; Barbara Eichhorst; Clemens-Martin Wendtner; Anton W Langerak; Karl-Anton Kreuzer; Matthias Ritgen; Valentin Goede; Stephan Stilgenbauer; Mehrdad Mobasher; Michael Hallek
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

5.  Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Authors:  Inhye E Ahn; Mohammed Z H Farooqui; Xin Tian; Janet Valdez; Clare Sun; Susan Soto; Jennifer Lotter; Stephanie Housel; Maryalice Stetler-Stevenson; Constance M Yuan; Irina Maric; Katherine R Calvo; Pia Nierman; Thomas E Hughes; Nakhle S Saba; Gerald E Marti; Stefania Pittaluga; Sarah E M Herman; Carsten U Niemann; Lone B Pedersen; Christian H Geisler; Richard Childs; Georg Aue; Adrian Wiestner
Journal:  Blood       Date:  2018-02-26       Impact factor: 22.113
  5 in total
  19 in total

1.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

2.  Upfront therapy: the case for continuous treatment.

Authors:  Constantine S Tam
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?

Authors:  Deborah M Stephens
Journal:  J Clin Oncol       Date:  2021-07-26       Impact factor: 44.544

4.  Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.

Authors:  Mariela Sivina; Ekaterina Kim; William G Wierda; Alessandra Ferrajoli; Nitin Jain; Philip Thompson; Hagop Kantarjian; Michael Keating; Jan A Burger
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

5.  Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Authors:  Inhye E Ahn; Carsten U Niemann; Christian Brieghel; Kathrine Aarup; Mathias H Torp; Michael A Andersen; Christina W Yde; Xin Tian; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2021-05-07       Impact factor: 13.801

6.  Significance of Tumor Mutation Burden Combined With Immune Infiltrates in the Progression and Prognosis of Advanced Gastric Cancer.

Authors:  Xiong Guo; Xiaolong Liang; Yujun Wang; Anqi Cheng; Han Zhang; Chuan Qin; Ziwei Wang
Journal:  Front Genet       Date:  2021-07-09       Impact factor: 4.599

Review 7.  Targeting Bruton's Tyrosine Kinase in CLL.

Authors:  Inhye E Ahn; Jennifer R Brown
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

8.  BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.

Authors:  Maissa Mhibik; Erika M Gaglione; David Eik; Ellen K Kendall; Amy Blackburn; Keyvan Keyvanfar; Maria Joao Baptista; Inhye E Ahn; Clare Sun; Junpeng Qi; Christoph Rader; Adrian Wiestner
Journal:  Blood       Date:  2021-11-11       Impact factor: 22.113

Review 9.  Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

Review 10.  First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?

Authors:  Hua-Jay J Cherng; Nitin Jain
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.